Nunzia Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nunzia pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nunzia Pharmaceutical Today - Breaking & Trending Today

Alzheimer's Disease is the leading cause of Dementia; Alzheimer's Diagnostics Attained by Global WholeHealth Partners, Corp (OTC: GWHP) as a Leading Researcher


Share this article
Share this article
SAN CLEMENTE, Calif., May 6, 2021 /PRNewswire/ Global WholeHealth Partners Corp (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests attains breakthrough on rising neurological disease.
This could simply be described as nothing short of a Medical Breakthrough in Alzheimer s Disease Diagnostic Testing for us - said Charles Strongo, CEO of Global WholeHealth Partners, Corp (OTC:GWHP)
Global WholeHealth Partners now has the means to identify and test for Alzheimer s disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking ....

United States , Charles Strongo , Global Wholehealth Partners Corp , Exchange Commission , Company Annual Report On Form , Prnewswire Global Wholehealth Partners Corp , Wholehealth Partners Corp , Diagnostic Tests , Medical Breakthrough , Disease Diagnostic Testing , Global Wholehealth Partners , Wholehealth Partners , Micro Well Reader , Lateral Flow Test , Nunzia Pharmaceutical , Troponini Whole Blood , Rapid Ebola , Rapid Dengue Fever Antibody , Rapid Tuberculosis , Rapid Malaria , Annual Report , Quarterly Reports , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , கண்டறியும் சோதனைகள் ,

Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry


Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry
PALM BEACH, Fla., April 22, 2021 /PRNewswire/ There are more than 600 types of neuro-disorders affecting the brain, spine, or nerves. Although some prevalent disorders such as cerebral stroke, Alzheimer s disease, Parkinson s disease, brain tumors, and epilepsy, are well-studied, most neurological disorders are complicated and rare requiring further in-depth knowledge about the underlining pathophysiology. A report from Grand View Research recently said that the global neurological biomarkers market size was estimated at USD 5,564.8 million in 2018 and is expected to exhibit a CAGR of 14.5% during the forecast period. (2021-2028) Rising prevalence of neurological diseases and increasing emphasis on early diagnosis & treatment are expected to drive the market growth. Another report from Fortune Business Insight went even a little further saying that the globa ....

United States , Noord Holland , Russian Federation , Charles Strongo , Neurocrine Biosciences , Kostenloser Wertpapierhandel , Williamh Rastetter , Johanna Mercier , Global Wholehealth Partners Corp , Fn Media Group , View Research , Senseonics Holdings Inc , Nunzia Pharmaceutical Inc , Amsterdam Skills Centre , Neurocrine Biosciences Inc , Gilead Sciences , Exchange Commission , Parkinson Foundation , Asensus Surgical Inc , Securities Exchange , Grand View Research , Fortune Business Insight , Senseonics Holdings , Asensus Surgical , Wholehealth Partners Corp , Opening New Global Avenues ,